Global Valganciclovir API Market Research Report 2024

Publication ID:

PB506250287

Publication Date:

June 27, 2024

Pages:

101

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Specialty Chemicals [2]

Manufacturing (Chemicals) [3]

Chemicals [4]

Description:

Valganciclovir(CAS锛�175865-60-8) also called Valgancyclovir,is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant.
The global Valganciclovir API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Valganciclovir API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Valganciclovir API.
Report Scope
The Valganciclovir API market size, estimations, and forecasts are provided in terms of output/shipments (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Valganciclovir API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Valganciclovir API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biophore India Pharmaceuticals Pvt Ltd
Mylan
Extrovis AG
Aurore Life Sciences
Hetero Drugs
Calyx Chemicals & Pharmaceuticals Limited
DEAFARMA
Aspire Lifesciences Pvt Ltd
Rakshit Drugs
Anthem Biosciences
Hanways Chempharm Co., Limited
Segment by Type
Above 98 %
Above 99 %
Segment by Application
Tablets
Oral Solution
Others
Production by Region
North America
Europe
China
India
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Mexico
Brazil
Turkey
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Valganciclovir API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Valganciclovir API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Valganciclovir API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Valganciclovir API Market Overview
1.1 Product Definition
1.2 Valganciclovir API Segment by Type
1.2.1 Global Valganciclovir API Market Value Growth Rate Analysis by Type 2023 VS 2030
1.2.2 Above 98 %
1.2.3 Above 99 %
1.3 Valganciclovir API Segment by Application
1.3.1 Global Valganciclovir API Market Value Growth Rate Analysis by Application: 2023 VS 2030
1.3.2 Tablets
1.3.3 Oral Solution
1.3.4 Others
1.4 Global Market Growth Prospects
1.4.1 Global Valganciclovir API Production Value Estimates and Forecasts (2019-2030)
1.4.2 Global Valganciclovir API Production Capacity Estimates and Forecasts (2019-2030)
1.4.3 Global Valganciclovir API Production Estimates and Forecasts (2019-2030)
1.4.4 Global Valganciclovir API Market Average Price Estimates and Forecasts (2019-2030)
1.5 Assumptions and Limitations
2 Market Competition by Manufacturers
2.1 Global Valganciclovir API Production Market Share by Manufacturers (2019-2024)
2.2 Global Valganciclovir API Production Value Market Share by Manufacturers (2019-2024)
2.3 Global Key Players of Valganciclovir API, Industry Ranking, 2022 VS 2023 VS 2024
2.4 Global Valganciclovir API Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.5 Global Valganciclovir API Average Price by Manufacturers (2019-2024)
2.6 Global Key Manufacturers of Valganciclovir API, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Valganciclovir API, Product Offered and Application
2.8 Global Key Manufacturers of Valganciclovir API, Date of Enter into This Industry
2.9 Valganciclovir API Market Competitive Situation and Trends
2.9.1 Valganciclovir API Market Concentration Rate
2.9.2 Global 5 and 10 Largest Valganciclovir API Players Market Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Valganciclovir API Production by Region
3.1 Global Valganciclovir API Production Value Estimates and Forecasts by Region: 2019 VS 2023 VS 2030
3.2 Global Valganciclovir API Production Value by Region (2019-2030)
3.2.1 Global Valganciclovir API Production Value Market Share by Region (2019-2024)
3.2.2 Global Forecasted Production Value of Valganciclovir API by Region (2025-2030)
3.3 Global Valganciclovir API Production Estimates and Forecasts by Region: 2019 VS 2023 VS 2030
3.4 Global Valganciclovir API Production by Region (2019-2030)
3.4.1 Global Valganciclovir API Production Market Share by Region (2019-2024)
3.4.2 Global Forecasted Production of Valganciclovir API by Region (2025-2030)
3.5 Global Valganciclovir API Market Price Analysis by Region (2019-2024)
3.6 Global Valganciclovir API Production and Value, Year-over-Year Growth
3.6.1 North America Valganciclovir API Production Value Estimates and Forecasts (2019-2030)
3.6.2 Europe Valganciclovir API Production Value Estimates and Forecasts (2019-2030)
3.6.3 China Valganciclovir API Production Value Estimates and Forecasts (2019-2030)
3.6.4 India Valganciclovir API Production Value Estimates and Forecasts (2019-2030)
4 Valganciclovir API Consumption by Region
4.1 Global Valganciclovir API Consumption Estimates and Forecasts by Region: 2019 VS 2023 VS 2030
4.2 Global Valganciclovir API Consumption by Region (2019-2030)
4.2.1 Global Valganciclovir API Consumption by Region (2019-2024)
4.2.2 Global Valganciclovir API Forecasted Consumption by Region (2025-2030)
4.3 North America
4.3.1 North America Valganciclovir API Consumption Growth Rate by Country: 2019 VS 2023 VS 2030
4.3.2 North America Valganciclovir API Consumption by Country (2019-2030)
4.3.3 United States
4.3.4 Canada
4.4 Europe
4.4.1 Europe Valganciclovir API Consumption Growth Rate by Country: 2019 VS 2023 VS 2030
4.4.2 Europe Valganciclovir API Consumption by Country (2019-2030)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Valganciclovir API Consumption Growth Rate by Region: 2019 VS 2023 VS 2030
4.5.2 Asia Pacific Valganciclovir API Consumption by Region (2019-2030)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Valganciclovir API Consumption Growth Rate by Country: 2019 VS 2023 VS 2030
4.6.2 Latin America, Middle East & Africa Valganciclovir API Consumption by Country (2019-2030)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
4.6.6 GCC Countries
5 Segment by Type
5.1 Global Valganciclovir API Production by Type (2019-2030)
5.1.1 Global Valganciclovir API Production by Type (2019-2024)
5.1.2 Global Valganciclovir API Production by Type (2025-2030)
5.1.3 Global Valganciclovir API Production Market Share by Type (2019-2030)
5.2 Global Valganciclovir API Production Value by Type (2019-2030)
5.2.1 Global Valganciclovir API Production Value by Type (2019-2024)
5.2.2 Global Valganciclovir API Production Value by Type (2025-2030)
5.2.3 Global Valganciclovir API Production Value Market Share by Type (2019-2030)
5.3 Global Valganciclovir API Price by Type (2019-2030)
6 Segment by Application
6.1 Global Valganciclovir API Production by Application (2019-2030)
6.1.1 Global Valganciclovir API Production by Application (2019-2024)
6.1.2 Global Valganciclovir API Production by Application (2025-2030)
6.1.3 Global Valganciclovir API Production Market Share by Application (2019-2030)
6.2 Global Valganciclovir API Production Value by Application (2019-2030)
6.2.1 Global Valganciclovir API Production Value by Application (2019-2024)
6.2.2 Global Valganciclovir API Production Value by Application (2025-2030)
6.2.3 Global Valganciclovir API Production Value Market Share by Application (2019-2030)
6.3 Global Valganciclovir API Price by Application (2019-2030)
7 Key Companies Profiled
7.1 Biophore India Pharmaceuticals Pvt Ltd
7.1.1 Biophore India Pharmaceuticals Pvt Ltd Valganciclovir API Corporation Information
7.1.2 Biophore India Pharmaceuticals Pvt Ltd Valganciclovir API Product Portfolio
7.1.3 Biophore India Pharmaceuticals Pvt Ltd Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.1.4 Biophore India Pharmaceuticals Pvt Ltd Main Business and Markets Served
7.1.5 Biophore India Pharmaceuticals Pvt Ltd Recent Developments/Updates
7.2 Mylan
7.2.1 Mylan Valganciclovir API Corporation Information
7.2.2 Mylan Valganciclovir API Product Portfolio
7.2.3 Mylan Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.2.4 Mylan Main Business and Markets Served
7.2.5 Mylan Recent Developments/Updates
7.3 Extrovis AG
7.3.1 Extrovis AG Valganciclovir API Corporation Information
7.3.2 Extrovis AG Valganciclovir API Product Portfolio
7.3.3 Extrovis AG Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.3.4 Extrovis AG Main Business and Markets Served
7.3.5 Extrovis AG Recent Developments/Updates
7.4 Aurore Life Sciences
7.4.1 Aurore Life Sciences Valganciclovir API Corporation Information
7.4.2 Aurore Life Sciences Valganciclovir API Product Portfolio
7.4.3 Aurore Life Sciences Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.4.4 Aurore Life Sciences Main Business and Markets Served
7.4.5 Aurore Life Sciences Recent Developments/Updates
7.5 Hetero Drugs
7.5.1 Hetero Drugs Valganciclovir API Corporation Information
7.5.2 Hetero Drugs Valganciclovir API Product Portfolio
7.5.3 Hetero Drugs Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.5.4 Hetero Drugs Main Business and Markets Served
7.5.5 Hetero Drugs Recent Developments/Updates
7.6 Calyx Chemicals & Pharmaceuticals Limited
7.6.1 Calyx Chemicals & Pharmaceuticals Limited Valganciclovir API Corporation Information
7.6.2 Calyx Chemicals & Pharmaceuticals Limited Valganciclovir API Product Portfolio
7.6.3 Calyx Chemicals & Pharmaceuticals Limited Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.6.4 Calyx Chemicals & Pharmaceuticals Limited Main Business and Markets Served
7.6.5 Calyx Chemicals & Pharmaceuticals Limited Recent Developments/Updates
7.7 DEAFARMA
7.7.1 DEAFARMA Valganciclovir API Corporation Information
7.7.2 DEAFARMA Valganciclovir API Product Portfolio
7.7.3 DEAFARMA Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.7.4 DEAFARMA Main Business and Markets Served
7.7.5 DEAFARMA Recent Developments/Updates
7.8 Aspire Lifesciences Pvt Ltd
7.8.1 Aspire Lifesciences Pvt Ltd Valganciclovir API Corporation Information
7.8.2 Aspire Lifesciences Pvt Ltd Valganciclovir API Product Portfolio
7.8.3 Aspire Lifesciences Pvt Ltd Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.8.4 Aspire Lifesciences Pvt Ltd Main Business and Markets Served
7.7.5 Aspire Lifesciences Pvt Ltd Recent Developments/Updates
7.9 Rakshit Drugs
7.9.1 Rakshit Drugs Valganciclovir API Corporation Information
7.9.2 Rakshit Drugs Valganciclovir API Product Portfolio
7.9.3 Rakshit Drugs Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.9.4 Rakshit Drugs Main Business and Markets Served
7.9.5 Rakshit Drugs Recent Developments/Updates
7.10 Anthem Biosciences
7.10.1 Anthem Biosciences Valganciclovir API Corporation Information
7.10.2 Anthem Biosciences Valganciclovir API Product Portfolio
7.10.3 Anthem Biosciences Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.10.4 Anthem Biosciences Main Business and Markets Served
7.10.5 Anthem Biosciences Recent Developments/Updates
7.11 Hanways Chempharm Co., Limited
7.11.1 Hanways Chempharm Co., Limited Valganciclovir API Corporation Information
7.11.2 Hanways Chempharm Co., Limited Valganciclovir API Product Portfolio
7.11.3 Hanways Chempharm Co., Limited Valganciclovir API Production, Value, Price and Gross Margin (2019-2024)
7.11.4 Hanways Chempharm Co., Limited Main Business and Markets Served
7.11.5 Hanways Chempharm Co., Limited Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Valganciclovir API Industry Chain Analysis
8.2 Valganciclovir API Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Valganciclovir API Production Mode & Process
8.4 Valganciclovir API Sales and Marketing
8.4.1 Valganciclovir API Sales Channels
8.4.2 Valganciclovir API Distributors
8.5 Valganciclovir API Customers
9 Valganciclovir API Market Dynamics
9.1 Valganciclovir API Industry Trends
9.2 Valganciclovir API Market Drivers
9.3 Valganciclovir API Market Challenges
9.4 Valganciclovir API Market Restraints
10 Research Finding and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 Market Size Estimation
11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer

Companies Mentioned:

Biophore India Pharmaceuticals Pvt Ltd
Mylan
Extrovis AG
Aurore Life Sciences
Hetero Drugs
Calyx Chemicals & Pharmaceuticals Limited
DEAFARMA
Aspire Lifesciences Pvt Ltd
Rakshit Drugs
Anthem Biosciences
Hanways Chempharm Co., Limited

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂